On June 17, Shattuck Labs (STTK.US) announced the latest mid-term data from its phase 1b dose expansion clinical trial of the investigational therapy SL-172154. The analysis showed that when used in combination with azacitidine (AZA) as a first-line therapy for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) patients with TP53 mutation (TP53m), the objective response rate (ORR) of patients reached 67% and 43%, respectively.

SL-172154 (SIRPα-Fc-CD40L) is an investigational redirected checkpoint agonist (ARC) fusion protein that aims to simultaneously inhibit the interaction of the CD47/SIRPα checkpoint and activate the CD40 co-stimulatory receptor to enhance the anti-tumor immune response of late-stage cancer patients. Currently, the therapy is undergoing several phase 1 clinical trials, including its use in platinum-resistant ovarian cancer patients, AML, and HR-MDS patients.